Cargando…

Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome

BACKGROUND: Low molecular weight heparins (LMWHs) are the mainstay of treatment for acute coronary syndrome (ACS). However, bleeding, the main side effect, is associated with prolonged hospitalization and mortality. Therefore, assessment of the incidence of bleeding and associated risk factors is cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Weerasaksanti, Adisak, Siwamogsatham, Sarawut, Kunlamas, Yotsaya, Bunditanukul, Krittin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164346/
https://www.ncbi.nlm.nih.gov/pubmed/37149613
http://dx.doi.org/10.1186/s12872-023-03278-9
_version_ 1785038049676099584
author Weerasaksanti, Adisak
Siwamogsatham, Sarawut
Kunlamas, Yotsaya
Bunditanukul, Krittin
author_facet Weerasaksanti, Adisak
Siwamogsatham, Sarawut
Kunlamas, Yotsaya
Bunditanukul, Krittin
author_sort Weerasaksanti, Adisak
collection PubMed
description BACKGROUND: Low molecular weight heparins (LMWHs) are the mainstay of treatment for acute coronary syndrome (ACS). However, bleeding, the main side effect, is associated with prolonged hospitalization and mortality. Therefore, assessment of the incidence of bleeding and associated risk factors is crucial in developing an appropriate treatment plan to prevent bleeding. METHODS: A retrospective cohort study was conducted in patients with ACS admitted to a university hospital in Bangkok, Thailand between 2011 and 2015 and received enoxaparin. To estimate the incidence of bleeding events, patients were followed up for 30 days from the first enoxaparin dose. Multiple logistic regression was used to determine factors associated with bleeding events. RESULTS: From a total of 602 patients, the incidence of bleeding was 15.8%, of which 5.7% involved major bleeding. The risk factors for any form of bleeding were aged at least 65 years (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.18 to 3.36), history of bleeding (OR, 3.79; 95% CI, 1.24 to 11.55), and history of oral anticoagulant exposure (OR, 4.73; 95% CI, 1.74 to 12.86). CONCLUSION: ACS patients treated with enoxaparin had an increased risk of bleeding if they were aged 65 years or older, had a history of bleeding events, and had a history of taking oral anticoagulants.
format Online
Article
Text
id pubmed-10164346
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101643462023-05-08 Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome Weerasaksanti, Adisak Siwamogsatham, Sarawut Kunlamas, Yotsaya Bunditanukul, Krittin BMC Cardiovasc Disord Research BACKGROUND: Low molecular weight heparins (LMWHs) are the mainstay of treatment for acute coronary syndrome (ACS). However, bleeding, the main side effect, is associated with prolonged hospitalization and mortality. Therefore, assessment of the incidence of bleeding and associated risk factors is crucial in developing an appropriate treatment plan to prevent bleeding. METHODS: A retrospective cohort study was conducted in patients with ACS admitted to a university hospital in Bangkok, Thailand between 2011 and 2015 and received enoxaparin. To estimate the incidence of bleeding events, patients were followed up for 30 days from the first enoxaparin dose. Multiple logistic regression was used to determine factors associated with bleeding events. RESULTS: From a total of 602 patients, the incidence of bleeding was 15.8%, of which 5.7% involved major bleeding. The risk factors for any form of bleeding were aged at least 65 years (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.18 to 3.36), history of bleeding (OR, 3.79; 95% CI, 1.24 to 11.55), and history of oral anticoagulant exposure (OR, 4.73; 95% CI, 1.74 to 12.86). CONCLUSION: ACS patients treated with enoxaparin had an increased risk of bleeding if they were aged 65 years or older, had a history of bleeding events, and had a history of taking oral anticoagulants. BioMed Central 2023-05-06 /pmc/articles/PMC10164346/ /pubmed/37149613 http://dx.doi.org/10.1186/s12872-023-03278-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Weerasaksanti, Adisak
Siwamogsatham, Sarawut
Kunlamas, Yotsaya
Bunditanukul, Krittin
Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title_full Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title_fullStr Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title_full_unstemmed Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title_short Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
title_sort factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164346/
https://www.ncbi.nlm.nih.gov/pubmed/37149613
http://dx.doi.org/10.1186/s12872-023-03278-9
work_keys_str_mv AT weerasaksantiadisak factorsassociatedwithbleedingeventsfromenoxaparinusedforpatientswithacutecoronarysyndrome
AT siwamogsathamsarawut factorsassociatedwithbleedingeventsfromenoxaparinusedforpatientswithacutecoronarysyndrome
AT kunlamasyotsaya factorsassociatedwithbleedingeventsfromenoxaparinusedforpatientswithacutecoronarysyndrome
AT bunditanukulkrittin factorsassociatedwithbleedingeventsfromenoxaparinusedforpatientswithacutecoronarysyndrome